布地奈德和孟鲁司特佐治儿童肺炎支原体肺炎效果

ADJUVANT THERAPY WITH BUDESONIDE ATOMIZATION INHALATION VERSUS ORAL MONTELUKAST FOR THE TREATMENT IN CHILDREN WITH MYCOPLASMA PNEUMONIAE PNEUMONIA

目的比较布地奈德雾化吸入与孟鲁司特口服佐治儿童肺炎支原体肺炎的效果及对继发性气道高反应性的影响。方法选取肺炎支原体肺炎病儿120例,随机分为A、B、C组。3组均给予阿奇霉素治疗3个疗程,其中B组加用布地奈德雾化吸入10d,C组加用孟鲁司特口服3周。比较3组疗效及最大呼气流量(PEF)变异率。结果治疗后10d,B组、C组总有效率均显著高于A组(χ2=8.658、6.646,P<0.05)。治疗前和治疗后10d,3组PEF变异率差异无显著性(P>0.05);随访3个月时,C组PEF变异率明显低于A组、B组(P<0.01)。结论布地奈德雾化吸入、孟鲁司特口服佐治儿童肺炎支原体肺炎临床效果确切,孟鲁司特能有效降低继发性气道高反应性。

Objective To compare the effect of adjuvant therapy with budesonide atomization inhalation versus oral montelukast for the treatment in children with Mycoplasma pneumoniae pneumonia（MPP）and its effect on secondary airway hyper-responsiveness. Methods This study consisted of 120 children with MPP and evenly randomized to three groups as A,B and C.Patients in the three groups were all given azithromycin for three courses of treatment,and those in group B added with budesonide atomization inhalation for 10 days,while those in group C oral montelukast was given for 3weeks.The efficacy and the aberration rate of peak expiratory flow（PEF）were compared between the three groups. Results Ten days after treatment,the total effective rates in groups B and C were higher than that in group A（χ2=8.658,6.646;P〈0.05）.No significant differences in PEF aberration rates between before and after 10-day treatment were observed in the three groups,and at three-month follow-up,the PEF aberration rate in group C was much lower than that in groups A and B（P〈0.01）. Conclusion Adjuvant therapy with budesonide atomization inhalation or oral montelukast for Mycoplasma pneumoniae pneumonia can obtain definite clinical efficacy,and montelukast can effectively reduce secondary airway hyper-responsiveness.